FGF23 and chronic kidney disease: For instance, Di Marco et al. showed that the progression of cardiac hypertrophy and cardiac fibrosis could be reduced by antibody-mediated blockage of the FGF receptor [30], which would also help revert the CKD-associated mineral and bone disorders, as both the decrease in vitamin D and the increase in PTH are FGF-23-mediated [28,29,31].